1192-P: Dapagliflozin Reduces Intrahepatic Triglyceride Content in Japanese Patients with Type 2 Diabetes Treated with Oral Antidiabetic Agents: A Randomized, Clinical Trial

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1192-P
Author(s):  
KATSUTARO MORINO ◽  
KEIKO KONDO ◽  
SACHIKO TANAKA ◽  
ITSUKO MIYAZAWA ◽  
KEIKO FUSE ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Japanese Patients ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic ◽  
Triglyceride Content

scholarly journals Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4

2010 ◽  
Vol 7 (3) ◽  
pp. 3-6
Author(s):  
G R Galstyan
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Pancreatic Beta Cell ◽  
Glucagon Secretion ◽  
Efficacy And Safety ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic ◽  
Dipeptidyl Peptidase Iv Inhibitors

Type 2 diabetes is difficult to manage and multiple therapeutic approach are usually needed. Moreover, addition to the initial treatment of most currently available oral antidiabetic agents increases the risk of hypoglycaemia and causes a weight gain. Dipeptidyl peptidase-IV inhibitors improve glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate glucagon secretion. This article summarizes the data from randomized clinical trial in which efficacy and safety of vildagliptin were assessed.

Sign in / Sign up

Export Citation Format

Share Document